Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Mayne Pharma (MYX AU): Scheme Booklet Dispatch Lends More Than A Veneer Of Support

Mayne Pharma (MYX AU): Firm Support From Cosette Would Be Welcome About Now

Quiddity Advisors

Event-Driven

<ul>
<li>
<strong>I have no clue</strong>. Given this is unchartered territory, in Australia, I don't believe anyone has a perfect handle on the situation</li>
<li>What do we know? The Second Court meeting has been pushed out to the 18th September from 20th June initially, to "<em>enable the dispute with Cosette</em>". </li>
<li>This date may be further delayed as a court hearing will commence on the 9th September to hear the validity of Cosette's termination notice.</li>
</ul>



I have no clue. Given this is unchartered territory, in Australia, I don't believe anyone has a perfect handle on the situation
What do we know? The Second Court meeting has been pushed out to the 18th September from 20th June initially, to "enable the dispute with Cosette". 
This date may be further delayed as a court hearing will commence on the 9th September to hear the validity of Cosette's termination notice.


Mayne Pharma (MYX AU): The Vote Gets Up. Now What?